Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mission creep, rebates, uncertainty, inertia: the challenges in major HTAs

This article was originally published in Scrip

Executive Summary

As a symptom of the impact that registration and reimbursement difficulties in Europe can have, Eisai has decided to make emerging markets such as Russia and Saudi Arabia priorities in the launch of its antiepileptic drug Fycompa (scripintelligence.com, 3 October 2012). With the 10th European Congress on Epileptology now in full swing in London (30 September– 4 October 2012), Gary Hendler, president and CEO of Eisai EMEA & Russia, explained to Scrip how complications in the major European markets had influenced the company's new product launch strategies.

You may also be interested in...



Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Australian Industry Maps Path To Better Use Of Real World Evidence

The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”

A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way

NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.

Topics

Related Companies

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel